SCHEMBL15068073

SCHEMBL15068073

Cc1c(-c2cccc(OCC(=O)NCCCCCCNC(=O)COc3cccc(-c4c(C)c(C(=O)c5ccc6[nH]c(=O)n(CC(=O)O)c(=O)c6c5)n5ccccc45)c3)c2)c2ccccn2c1C(=O)c1ccc2[nH]c(=O)n(CC(=O)O)c(=O)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
ADORA2B P29275 3/20 0.34
ADORA1 P30542 2/20 0.34
ADORA3 P0DMS8 2/20 0.34
ROCK2 O75116 1/20 0.34
HSD17B10 Q99714 3/20 0.34
GLA P06280 1/20 0.34
TP53 P04637 1/20 0.34
KDM4E B2RXH2 2/20 0.33
HPGD P15428 2/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
ADORA2A P29274 1/20 0.33
GAA P10253 1/20 0.33
MAPK10 P53779 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15067912 0.99 MEN1 (0.36) MEN1HTTKMT2AADORA2BADORA1
SCHEMBL15067653 0.93 ADORA2B (0.39) MEN1HTTKMT2AADORA2BADORA1
SCHEMBL15067925 0.93 ADORA2B (0.40) MEN1HTTKMT2AADORA2BADORA1
SCHEMBL15068198 0.90 ADORA2B (0.37) MEN1HTTKMT2AADORA2BADORA1
SCHEMBL15068075 0.89 MEN1 (0.38) MEN1HTTKMT2AADORA2BADORA1
SCHEMBL15067914 0.88 MEN1 (0.38) MEN1HTTKMT2AADORA2BADORA1
SCHEMBL15068195 0.87 ADORA2B (0.37) MEN1HTTKMT2AADORA2BADORA1
SCHEMBL15067756 0.87 MCL1 (0.35) KMT2AHSD17B10GLATP53KDM4E
SCHEMBL15067654 0.83 ADORA2B (0.40) MEN1HTTKMT2AADORA2BADORA1
SCHEMBL15067926 0.82 ADORA2B (0.40) MEN1HTTKMT2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797930-B1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-07-13 EP claimed
US-9206177-B2 Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists SANOFI (FR) 2015-12-08 US claimed
US-20140378483-A1 FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof SANOFI (FR) 2014-12-25 US claimed
EP-2797930-B1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-07-13 EP disclosed
EP-2797930-A1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-11-05 EP disclosed
WO-2013098763-A1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378483-A1 FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof FGFR1, FGFR2, FGF2 MEN1 1168/4885HTT 4644/4885KMT2A 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.